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Current magnetic resonance imaging (MRI) contrast agents often 
produce insufficient contrast for diagnosis of early disease stages, 
and do not sense their biochemical environments. Herein, we 
report a highly sensitive nanoparticle-based MRI probe with r1 
relaxivity up to 51.7 ± 1.2 mM
-1
s
-1
 (3T). Nanoparticles were co-
assembled from Gd
3+
 complexed to heparin-
poly(dimethylsiloxane) copolymer, and a reduction-sensitive 
amphiphilic peptide serving to induce responsiveness to 
environmental changes. The release of the peptide components 
leads to a r1 relaxivity increase under reducing conditions and 
increases the MRI contrast. In addition, this MRI probe has several 
advantages, such as a low cellular uptake, no apparent cellular 
toxicity (tested up to 1 mM Gd
3+
), absence of an anticoagulation 
property, and a high shelf stability (no increase in free Gd
3+
 over 7 
months). Thus, this highly sensitive T1 MRI contrast nanoparticle 
system represents a promising probe for early diagnosis through 
possible accumulation and contrast enhancement within reductive 
extracellular tumour tissue. 
Magnetic resonance imaging (MRI) is a non-invasive technique 
that is widely used in cardiovascular, neurological, and 
oncological diagnostics.
1
 Imaging is based on contrast 
generated by tissue-dependant variations in either the 
longitudinal (T1) or transverse (T2) relaxation times of the 
proton nuclear spins of water molecules, combined with 
paramagnetic contrast agents (CAs) that shorten the relaxation 
time of neighbouring water protons. CAs are characterized by 
their induced relaxivity (ri), defined as the change in relaxation 
rate (∆(1/Ti)), normalized to their concentrations.
2
 An 
important class of CAs is based on Gd
3+
 complexed with 
various ligands to avoid the intrinsic toxicity of free Gd
3+
 ions. 
Gd-based CAs approved for clinical use typically have an r1 of 
4–5 mM
-1
s
-1
.
3
 These CAs are small molecules, which passively 
distribute after administration.
4
 However, commercially 
available Gd-CAs have a low efficiency, and high doses are 
required for good contrast enhancement.
3b, 5
  
Three main strategies are used to improve the contrast 
enhancement of MRI CAs: i) modifying the ligand to increase 
the number of free coordination sites at the metal centre, and 
thus exchange rates between bulk and coordinated water, ii) 
increasing Gd concentrations by accumulating multiple ligands 
within one macromolecule, and iii) forming bulky assemblies 
to lower the molecular tumbling rate (τR), as both high water 
exchange rates and decreased molecular tumbling contribute 
to faster relaxation and higher MRI contrast.
1
 In this regard, 
nanosized macromolecular CAs of various architectures have 
been reported, comprising micelles,
6
 dendrimers,
7
 vesicles,
8
 
and nanoparticles.
1, 9
 However, the efficiency of Gd-based CAs 
is influenced in a complex overall manner by various molecular 
and dynamic factors, and the gain in relaxivity is often far less 
than expected.
10
 Also, additional introduction of specificity and 
responsiveness of MRI CAs to distinct environments, such as 
inflamed tissue or tumour microenvironments, allows specific 
localization and diagnosis,
1, 11
 but the production of CAs that 
combine high r1 relaxivity and response to physiological 
parameters at pathologic sites remains a major challenge.  
Here we report a highly active MRI contrast agent with 
enhanced relaxivity in reductive milieu based on nanoparticles 
(NPs) resulting from co-assembly of heparin-polymers with 
trapped Gd
3+
 and stimuli-responsive peptides. The selection of 
the heparin–polymer conjugate was inspired by the strong 
Gd
3+
 complexing ability of the natural glycosaminoglycan 
heparin,
12,13
 and the long blood circulation behaviour of 
heparinized NPs.
14
 Long-circulating NPs can readily accumulate 
in tumour tissue via the leaky vasculature surrounding 
tumours (enhanced permeation and retention effect),
15
 which 
increases the efficiency of cancer imaging for disease 
diagnosis.
16
 Furthermore, elevated glutathione (GSH) levels in 
the extracellular environment of tumours, compared to 
healthy tissues, can be exploited as a trigger to further 
increase image contrast.
17
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We have now designed and synthesized an amphiphilic 
heparin-poly(dimethylsiloxane) (hepPDMS) block copolymer 
capable of self-assembling into NPs with complexation sites for 
Gd
3+
. A disulfide-linked amphiphilic peptide interacts with 
hepPDMS-Gd via the polyhistidine sequence and co-assembles 
to peptide-hepPDMS-Gd NPs (p-hepPDMS-Gd-NPs). The 
peptide sequence (H2N-H3-X-[W-DL]3-W-CONH2) contains a 
reducible linker X (X = -(CH2)2-S–S-(CH2)2-NH-CO-(CH2)2-CO-) 
that connects the hydrophobic L-tryptophan-D-leucine 
repeating unit and the oligohistidine (H3SSgT).
18
 In a reductive 
environment, the peptides are released, increasing the 
accessibility of Gd
3+
 for water molecules, and therefore 
increasing MRI contrast. 
HepPDMS was obtained by coupling heparin polysaccharide 
with commercial PDMS (5kDa) via reductive amination; this 
yielded an average of 25 heparin repeating units per PDMS 
chain, as previously reported.
19
 To create a NP-based Gd MRI 
CA, hepPDMS was mixed with a solution of GdCl3 (6.5 eq) in 
50% ethanol at pH 7.0. NPs were formed through solvent 
exchange from 50% ethanol to water via dialysis, which 
simultaneously removed uncomplexed Gd. The hepPDMS-Gd 
NPs (hepPDMS-Gd-NPs) had particle size of 51 ± 22 nm 
evaluated by dynamic light scattering (DLS), in agreement with 
that obtained from TEM micrographs (45 ± 16 nm) (Fig. 1A; 
S1). Successful complexation of Gd to the heparin-block of 
hepPDMS-Gd-NPs was indicated both by Fourier transform 
infrared spectroscopy (FTIR) and Farndale microassay (Fig. S2). 
The latter showed a significant decrease in accessible heparin 
chains on the NPs from 1170 ± 42 µg/mL (hepPDMS-NPs) to 
960 ± 49 µg/mL (hepPDMS-Gd-NPs) due to partial occupation 
of the dye-binding sites on heparin by Gd
3+
. The concentration 
of Gd complexed within the hepPDMS-NPs was determined to 
be 0.93 mM by inductively coupled plasma optical emission 
spectroscopy (ICP-OES), which is 77 % of the initial Gd 
concentration. It demonstrates the high complexing abilities of 
hepPDMS, and allows the creation of a high Gd-density within 
the NPs that is necessary for contrast enhancement in MRI. 
To introduce reduction-sensitivity to our NP-based MRI CA, the 
reduction-responsive amphiphilic peptide H3SSgT (0.5 mg/mL) 
was co-assembled with previously complexed hepPDMS-Gd to 
yield p-hepPDMS-Gd-NPs. The formed NPs were similar in size 
(DLS: 57 ± 38 nm, TEM: 43 ± 10 nm), and shape to those of 
hepPDMS-Gd-NPs (Fig. 1A,B; S1); a very small population of 
larger intensity weighted diameters (>300 nm) was also 
observed, and can be attributed to purely peptidic NPs (190 
nm).
18
 Use of higher concentrations of peptide (2 mg/mL) 
induced formation of large aggregates along with the co-
assemblies (Fig. S3), and thus further characterization of co-
assemblies was performed with a lower peptide concentration 
(0.5 mg/mL). Energy dispersive X-ray spectroscopy (EDX) 
analysis showed co-localization of Gd and sulfur (from the 
disulfide in the peptide and from hepPDMS) within the 
particles (Fig. S4). The expected interaction of the histidine 
residues of the peptide with the heparin block of hepPDMS 
when co-assembled was analyzed by Farndale microassays; the 
co-assembled peptide decreased the accessibility of heparin 
from 1020 ± 82 µg/mL to 760 ± 85 µg/mL. Since the assay  
Fig. 1 Schematic representation and TEM micrographs of (A) hepPDMS-Gd-NPs (B), p-
hepPDMS-Gd-NPs (-DTT), and (C) p-hepPDMS-Gd-NPs (+DTT). Sizes obtained by TEM 
are indicated. Scale bars: 200 nm.  
 
monitors the accessible heparin, these values represent the 
situation on the surfaces  
of the NPs rather than in their core, and also demonstrate 
steric hindrance originating from the co-assembled peptides. 
Zeta potential measurements revealed slightly different values 
(–55.0 ± 0.5 mV) for p-hepPDMS-Gd-NPs and NPs assembled 
without peptide (–58.0 ± 0.3 mV), but these are rather small 
for heparin is the most negatively charged biological 
macromolecule.
20
 At H3SSgT/hepPDMS-Gd ratios suitable for 
co-assembly, the number of histidines is insufficient to 
neutralize the charge of heparin, and the NPs are thus highly 
negatively charged. The preservation of heparin characteristics 
on the nanoparticle surfaces after Gd-complexation and co-
assembly with peptides provides the desired properties for 
prolonged blood circulation time,
14
 which is required for 
accumulation in tumour regions via the enhanced permeation 
and retention effect, and subsequent contrast enhancement 
for MRI diagnostics.
16
 For assessing size and morphology 
changes of p-hepPDMS-Gd-NPs upon reductive stimuli, they 
were treated with 10 mM dithiothreitol (DTT) in HEPES buffer 
at pH 7.2. This resulted in slightly decreased diameters (44 ± 
19 nm by DLS, 41 nm ± 8 nm by TEM) compared to hepPDMS-
Gd-NPs (Fig. 1A,C; S1). 
The suitability of these Gd-complexing NPs as MRI contrast 
agents was assessed in comparison with commercial Gd 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (Gd-
DOTA/Dotarem®), which is one of the most frequently applied 
CA in clinical MRI. At a field of 3T, Gd-DOTA had T1 relaxation 
times in a range of 1360 ms at 0.10 mM Gd and 213 ms at 0.99 
mM Gd (Fig. 2A, Table S1), resulting in a r1 relaxivity of 4.5 ± 
0.1 mM
-1
s
-1
 (Fig. 2C, Table S1), which is in agreement with 
literature values.
21
 However, when Gd was complexed within 
hepPDMS NPs, the water relaxivity increased to 51.7 ± 1.2 mM
-
1
s
-1
, which is more than an order of magnitude higher than for 
Gd-DOTA. This can be attributed mainly to decreased tumbling 
rates of the large NPs combined with different binding 
characteristics which create faster exchange rates at the metal 
centres. When co-assembled with H3SSgT, p-hepPDMS-Gd-NPs 
the r1 of 44.2 ± 1.5 mM
-1
s
-1
 (Fig. 2C, Table S1) was lower than 
for the purely hepPDMS-Gd-based nanoparticles. This may be 
because the close arrangement of the peptidic histidines to 
the heparin block of the copolymer increases the density of 
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Fig. 2 (A) T1 weighted MR image of a) Gd-DOTA, b) hepPDMS-Gd-NPs, c) p-hepPDMS-
Gd-NPs (-DTT), and d) p-hepPDMS-Gd-NPs (+DTT); concentration of each sample in μM 
is given in white. (B) EPR spectra of a) Gd-DOTA, b) hepPDMS-Gd-NPs, c) p-hepPDMS-
Gd-NPs (-DTT). (C) and (D) r1 and r2 relaxivity curves of p-hepPDMS-Gd (+DTT) (squares), 
p-hepPDMS-Gd (-DTT) (circles), and Gd-DOTA (triangles); r1 and r2 relaxivities are given 
in mM-1s-1. Detailed discussion of this figure is available in ESI
 
 the co-assembled particles, thereby sterically hindering water 
access and coordination to the metal centres.  
After addition of the reducing agent (DTT) an increase in r1 of 
about 20% to 54.4 ± 1.5 mM
-1
s
-1 
was obtained (Fig. 2C, Table 
S1), a value close to that of NPs assembled from hepPDMS-Gd 
alone. This increase in relaxivity in a reductive environment 
can be used to obtain increased contrast for cancerous tissue 
based on the elevated GSH-levels in extracellular space of 
tumours.
17
 Similar trends were also observed in T2 relaxation 
rates for the NPs compared to Gd-DOTA. For hepPDMS-Gd-NPs 
a transverse relaxation rate, r2, of 162.6 ± 17.8 mM
-1
s
-1
 was 
obtained, and this decreased to 103.5 ± 5.0 mM
-1
s
-1
 for 
particles co-assembled with H3SSgT and 108.4 ± 2.5 mM
-1
s
-1
 
after DTT addition (Fig. 2D, Table S1). These values are more 
than one order of magnitude higher than for Gd-DOTA (4.90 ± 
0.03 mM
-1
s
-1
) (a comparison of r1 relaxivities with experimental 
nanosized CAs is available in the ESI). 
To gain more insight into the behaviour of these Gd-
nanoparticles we used electron paramagnetic resonance (EPR) 
spectroscopy to calculate values of the transverse electronic 
relaxation rates, 1/T2e. Whilst the EPR spectra of Gd-DOTA, 
hepPDMS-Gd-NP and p-hepPDMS-Gd-NPs all have g-values 
around 2.00, those of both Gd-NPs have very broad lines and 
thus significantly different 1/T2e values from Gd-DOTA (Fig. 2B, 
Table S2). At a magnetic field of 0.34 T 1/T2e for Gd-DOTA was 
calculated as 1.31×10
9 
s
-1
,
22
 whereas the corresponding values 
for hepPDMS-Gd-NPs and p-hepPDMS-Gd-NPs were 6.56×10
9
 
s
-1
, and 5.98×10
9
 s
-1
, respectively. The decreased T2e can be 
explained by intramolecular dipole-dipole interactions 
between Gd ions in the NPs,
23
 the distribution of multiple Gd 
sites within the NPs and a slower rotational correlation time 
due to the size difference. These results are in agreement with 
previous reports that indicated increased proton relaxivity 
associated with rigid micelle-like structures.
24 
The
 
slight 
difference in 1/T2e between hepPDMS-Gd-NP and p-hepPDMS-
Gd-NP is due to the shielding effect of the co-assembled 
peptide. 
The high relaxivities r1 exhibited by hepPDMS-Gd-NPs, p-
hepPDMS-Gd-NPs, and DTT-treated p-hepPDMS-Gd-NPs 
indicate their potential for providing high contrast MRI. 
However, in order to be applicable in vivo, CAs should have no 
cellular toxicity. Thus we evaluated cell viability with HeLa 
cells, and various concentrations of p-hepPDMS-Gd-NPs, 
hepPDMS-Gd-NPs, and commercial Gd-DOTA. None of the 
particles showed any cellular toxicity up to 1.0 mM Gd (Fig. 
S5A). Since the absence of cellular toxicity could be the 
consequence of low cellular uptake as a result of the highly 
negative surface charge on our NPs, this was tested by 
incubating hepPDMS-Gd and p-hepPDMS-Gd nanoparticles 
with HeLa cells, then washing, digesting and quantifying the 
Gd content using ICP-OES; only small uptake of 2.8% and 5.4%, 
respectively was determined (Fig. S5B). This is advantageous 
because the desired long-circulation time within the blood 
stream, requires low cellular uptake, and subsequent fast 
removal from the body.  
Leakage of free Gd
3+
 ions from complexes/assemblies is 
associated with toxicity and represents another hurdle for 
translation towards an in vivo applicable MRI CA. Therefore, 
we quantified free Gd
3+
 in solution using a xylenol orange 
colorimetric assay. HepPDMS-Gd-NPs and p-hepPDMS-Gd-NPs 
showed that 8.5% and 5.9%, respectively of the Gd was 
present as free Gd
3+
. The level of free Gd
3+
 was unchanged by 
keeping the NPs for seven months at room temperature, 
although the NP partly rearranged to larger sizes, particularly 
for peptide co-assemblies (Fig. S6). This behaviour can be 
explained by slow sedimentation and subsequent aggregation 
of the NPs. Stability of the NPs was also investigated by 
incubation in cell growth media Gd levels remained below the 
detection limit of about 1 µM after seven days, although the 
sensitivity was limited by interaction of the colorimetric assay 
with the culture media. This concentration is considered 
noncritical since concentrations of 0.1–0.3 mmol/kg
25
 are 
normally applied for commercial MRI CAs, which have an r1 of 
4–5 mM
-1
s
-1
 and LD50 values for Gd of 0.5 mmol/kg in rats.
26
  
Heparin is known to exhibit anticoagulation properties, which 
are undesirable for MRI applications. Therefore, the 
anticoagulation activity of our system was evaluated using 
standard anti-Xa assays. It was found to be below the limit of 
detection of the assay (<0.1 U/mL) for hepPDMS-Gd-NPs and 
p-hepPDMS-Gd-NPs at concentrations of 700 and 580 µg/ml of 
accessible heparin (equivalent to 135 and 110 U/ml), 
respectively. Thus the anticoagulation ability of heparin is 
greatly reduced by conjugation to PDMS and subsequent NP 
formation.  
Responsive, high-relaxivity MRI contrast agents are in high 
demand for clinical diagnostics, and in this respect, p-
hepPDMS-Gd-NPs fulfil numerous key criteria for use as 
responsive high relaxivity CAs, and have an r1 relaxivity (44.2 
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mM
-1
s
-1
) that is tenfold higher than Gd-DOTA (4.5 mM
-1
s
-1
), 
which is currently considered to be the gold standard. 
Furthermore, addition of a reducing agent increased r1 by 
about 20% to 54.4 mM
-1
s
-1
. Thus the high values of r1 allow use 
of significantly lower doses of our NPs, whilst preserving high 
contrast for diagnostics. In addition, the triggered 
enhancement of r1 enables higher contrast generation in 
regions with increased reduction potential, such as cancerous 
tissue. In vitro cell assays demonstrated low cellular uptake, 
and the absence of cellular toxicity of the assembled NPs 
(comparable values for Gd-DOTA and NPs). Furthermore, they 
did not show any anticoagulation activity in vitro and were 
stable over seven months at room temperature. Thus our 
novel approach using natural complexing ligands for 
developing highly sensitive NP-based MRI CAs, which 
additionally have increased relaxivity in reducing environments, 
offers a promising direction for future optimization and 
application of these NPs. 
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